CerebrAlcare Pills on CereBral Small VesseL DiseasE（CABLE）

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

114 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-06-05

Study Completion Date

2024-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized, double-blinded, placebo-controlled, multicenter trial. Cerebral small vessel disease (CSVD) patients will be diagnosed by Magnetic Resonance Imaging (MRI) and randomized into treatment or control groups. The purpose of this trial is to assess the efficacy of cerebralcare pills on cerebral small vessel disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Songling Xuemaikang Capsules for Cerebral Small Vessel Disease

NCT07271732

Hypertension Cerebral Small Vessel Diseases

NOT_YET_RECRUITING NA

Effect of Tadalafil on Cerebral Large Arteries in Stroke

NCT02801032

Stroke, Lacunar Cerebral Small Vessel Diseases

COMPLETED PHASE2

In the Real World Study, the Efficacy and Adverse Reactions of Ticagrelor on Ischemic Cerebrovascular Disease

NCT05716646

Cerebral Infarction Stroke Nervous System Diseases +1 more

NOT_YET_RECRUITING

Tongxinluo Capsule in the Treatment of Cerebral Small Vessel Disease-A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study（TOPS-CSVD）

NCT06061692

Cerebral Small Vessel Diseases

NOT_YET_RECRUITING PHASE4

Efficacy and Safety Study of Endovascular Treatment of Asymptomatic Carotid Artery Stenosis

NCT06899399

Asymptomatic Carotid Artery Stenosis

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cerebral small vessel disease (CSVD) is prevalent in the aging population with insidious onset, almost affecting all levels of the brain vasculature, and challenges the social and healthcare system worldwide. CSVD is the major cause of 25% of strokes and more than doubles the odds of recurrent stroke; furthermore, it contributes to 45% of dementia cases and to global functional decline. However, an incomplete understanding of the pathogenesis of CSVD limits prevention and treatment efforts.

Cerebralcare Granule (CG) or Yangxue Qingnao granule, is a polyherbal medicine that was approved in 1997 by the China State Food and Drug Administration for the treatment of headaches and dizziness associated with cerebrovascular diseases. Cerebralcare pill is composed of 11 herbs. These herbs contain small molecules with various pharmacological actions. Cerebralcare pills have the same component as CG. Previous studies have demonstrated that CG significantly attenuated ischemia-reperfusion induced dysfunction, structural abnormalities in the microcirculation, and inflammatory injury. There are also studies confirming that CG also improved cognition function, improved cerebral microcirculation disorders, and hemodynamics.

Patients enrolled will be randomly assigned to either the treatment or control group to receive Brain Pill/Brain Pill placebo (from randomization to 6 months at a dose of 2 packs per day). Face-to-face interviews will be conducted at baseline, day 90, day 180, and 1 year after randomization.

The primary endpoint is the progression in cognition function which is assessed by Montreal Cognitive Assessment (MoCA) score. The secondary endpoints include changes in clinical characters, imaging markers (number and volume of white matter, number of lacunes, microbleeds, enlarged perivascular space ), hemodynamic parameters, Chinese medical symptoms, blood-brain barrier (BBB) permeability, proteomics, and inflammatory markers. The safety endpoints include severe hemorrhage events, symptomatic and asymptomatic intracranial hemorrhage, moderate hemorrhage, overall mortality, and serious adverse events.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cerebral Small Vessel Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cerebralcare pills placebo group

This group will receive Cerebralcare pills placebo, 2 packages, twice a day, from the day of randomization to 6 months.

Group Type PLACEBO_COMPARATOR

Cerebralcare pills placebo

Intervention Type DRUG

Cerebralcare pills placebo will be administrated at the same rate with experimental group

Cerebralcare pills group

This group will receive Cerebralcare pills, 2 packages, twice a day, from the day of randomization to 6 months.

Group Type EXPERIMENTAL

Cerebralcare pills

Intervention Type DRUG

a dose of 2 packages, twice a day of Cerebralcare pills

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cerebralcare pills

a dose of 2 packages, twice a day of Cerebralcare pills

Intervention Type DRUG

Cerebralcare pills placebo

Cerebralcare pills placebo will be administrated at the same rate with experimental group

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. 45-75 years old;
2. No gender limitation;
3. Cerebral small vessel disease is observed on brain MRI. White matter hyperintensity, Fazekas score ≥ 1 and combined more than 2 vascular risk factors (hypertension, hyperlipidemia, diabetes, obesity, smoking, and other vascular events except stroke) or combined with lacunar focus or Imaging findings suggest new subcortical lacunar infarction (within 7 days).
4. Mild or moderate vascular cognitive impairment(16 ≤ MoCA ≤ 24 score, for patients with primary school degree or below,15 ≤ MoCA ≤ 23 score).
5. Daily life independence (mRS ≤ 2).
6. Sign informed consent.

Note:

1. The imaging definition of small vessel disease refers to the strong guideline The total score of Fazekas was 6, which was the sum of Fazekas scores of subcortical and periventricular white matter lesions.
2. New subcortical lacunar infarction: head MRI examination, subcortical, basal ganglia or brain stem DWI showed high signal (ADC diffusion limited) lesions with diameter \< 20 mm, with or without corresponding clinical symptoms; There were new clinical symptoms. FLAIR sequence of head MRI showed flair hyperintense lesions (diameter \< 20 mm) in subcortical, basal ganglia or pons.

Exclusion Criteria

1. Cerebral hemorrhage and subarachnoid hemorrhage occurred within 30 days.
2. Symptomatic middle cerebral artery and/or internal carotid artery stenosis, stenosis rate ≥ 50%; asymptomatic middle cerebral artery and/or internal carotid artery stenosis, stenosis rate ≥ 70%.
3. Coronary CTA or coronary angiography showed severe three vessel lesions or frequent angina pectoris within 30 days.
4. Chronic kidney disease stage 4 or 5.
5. Resistant hypertension which could not be controlled by medicine (SBP \> 180mmHg or DBP \> 110mmHg).
6. Resistant hyperglycemia which could not be controlled by medicine（fasting blood glucose \> 10mmol/L or HB1AC \> 7%).
7. In acute cerebral infarction, the lesions showed high signal intensity on DWI, and the diameter was more than 20 mm or history of assive cerebral infarction within 30 days.
8. Neurodegenerative diseases, such as AD and PD, have been diagnosed.
9. There are clear non angiogenic white matter lesions, such as multiple sclerosis, adult white matter dysplasia, metabolic encephalopathy diseases, etc.
10. Untreated cerebrovascular malformations or intracranial aneurysms (d \> 3mm).
11. Active gastrointestinal bleeding.
12. Coagulation dysfunction or history of systemic bleeding.
13. Hemorrhagic tendency (including but not limited to)：PLT\<100×109/L; heparin treatment within 48h; APTT ≥ 35s; current use of warfarin, INR \> 1.7; current use of novel oral anticoagulants; current use of direct thrombin or factor Xa inhibitor.
14. Severe hepatic or renal or heat insufficiency before randomization (severe hepatic insufficiency refers to ALT or AST \> 2 times the upper limit of normal; severe renal insufficiency refers to serum creatinine\> 1.5 times the upper limit of normal or eGFR\<40 ml/min/1.73m2; severe heat insufficiency refers to NYHA stage 3 and 4).
15. History of intracranial or intramedullary surgery within three months of randomization.
16. The patient has used or is using chinese medicine with similar components to CerebrAlcare pill/granule (including Tianshu capsule, Toutongning capsule, Naoxintong capsule, Danzhen Toutou capsule, Yindanxinnaotong soft capsule, Naoxinqing Tablet, Bazhen pill and Shiquandabu pill) within 14 days.
17. Definite indications for anticoagulation (suspicion of cardioembolism, e.g. atrial fibrillation, known heart valve prosthesis, atrial myxoma, endocarditis, etc.) or definite indications for dual antiplatelet therapy (e.g. recent coronary or cerebral artery stent implantation).
18. Other surgical or interventional therapy planned within 1 year requiring experimental drugs discontinuation.
19. Childbearing-age women who do not take effective methods of contraception without negative records of pregnancy tests.
20. Known to be allergic to CerebrAlcare pill/granule.
21. Contraindications of MRI examination (such as claustrophobia).
22. With severe organic diseases, such as malignant tumor, the expected survival time is less than 1 years.
23. Due to geographical or other reasons can not cooperate to complete the follow-up.
24. Patients also participated in other clinical trials.

Minimum Eligible Age

45 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No